

# NVP-BHG712

Catalog No: tcsc0469



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

940310-85-0

**Formula:**

$C_{26}H_{20}F_3N_7O$

**Pathway:**

Protein Tyrosine Kinase/RTK

**Target:**

Ephrin Receptor

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**

503.48

## Product Description

NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows


activity against c-Raf, c-Src and c-Abl with IC<sub>50</sub> of 0.395  $\mu$ M, 1.266  $\mu$ M and 1.667  $\mu$ M, respectively.

IC<sub>50</sub> value: 25 nM(EC<sub>50</sub>)

Target: EphB4 receptor; c-Raf; c-Src

in vitro: NVP-BHG712 treatment also dose dependently leads to the inhibition of RTK autophosphorylation in stable transfected A375 melanoma cells with EC<sub>50</sub> of 25 nM and 4.2  $\mu$ M for EphB4 and VEGFR2, respectively [1].

in vivo: In a growth factor-induced angiogenesis model, NVP-BHG712 (3 mg/kg, p.o) significantly suppresses VEGF stimulated tissue formation and vascularization by inhibiting EphB4 forward signaling. Furthermore, NVP-BHG712 (10 mg/kg/kg, p.o.) potently reverses VEGF enhanced tissue formation and vessel growth. NVP-BHG712 (3 mg/kg, p.o.) shows a long lasting exposure with concentrations around 10  $\mu$ M in plasma as well as in lung and liver tissue for up to 8 hours, and thus results in a long lasting inhibition of EphB4 kinase activity in mice [1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!